Support for the show comes from Odoo. Running a business shouldn't feel like surviving a software group project. One app for accounting, another for inventory, another for sales, and somehow, none of them talk to each other. That's where Odoo comes in. An all-in-one business management software that brings every part of your business together. From sales and accounting to inventory and marketing, all in one powerful platform. No messy integrations, no bouncing between tabs. Best of all, no spreadsheets. Stop managing software and start managing your business with one unified system. Try for free today at odoo.com slash propg. That's O-D-O-O dot com slash propg.
Computers are getting smarter, Silicon Valley's getting weirder, and AI is taking over. At least that's what everyone keeps telling us. Welcome to Machine Gods, a new NPR podcast that will be your field guide to the AI-powered future. We're veteran tech journalists with front-row seats to the industry. And twice a week, we'll make sure you get smarter about AI, so you know what's real, what's hype, and what might come next. Listen to Machine Gods from NPR on the NPR app, or wherever you get your podcasts.
Are you a pet owner? Every six seconds, a pet owner in the U.S. gets hit with a vet bill over $1,000. Always an unwelcome surprise. That's where Fetch comes in. Fetch is the most complete pet insurance for dogs and cats, according to ConsumerAdvocate.org. You get paid back up to 90% of vet bills at any vet in the U.S. and Canada, with claims paid back in as little as two days. Go to FetchPet.com slash save right now for your free quote. That's FetchPet.com slash save. I'm Scott Galloway, and this is No Mercy, No Malice.
God, I'm sick of talking about SpaceX. More impressive than the Falcon Heavy rocket, and it is impressive, is Elon Inc.'s ability to manufacture scarcity. Getting the NASDAQ to waive requirements applied to every company until now so he can force index funds to purchase shares aims a demand cannon of $75 billion at a business with a small float.
The result is a price that in no way reflects the underlying value. But I digress. This isn't an investment, but a trade. So where to invest? The technology with the greater asymmetric upside, as well as the clearest path to transforming the economy and the well-being of more than 200 million Americans, isn't Falcon 9 boosters or GPT-5, but GLP-1s.
U.S. obesity rates have tripled over the last 60 years. Our instincts, developed over hundreds of thousands of years when food was scarce, haven't kept pace with industrial production, so we gorge. Obesity is a comorbidity for 200-plus chronic diseases, the central node in a network of poor health outcomes. The total bill for national health expenditures, including public and private spending, is $5.3 trillion.
By 2033, one out of every five dollars in the economy will go to health care. This is the IED at the center of the U.S. economy. Five years ago, when Ozempic and Wagovi were first approved for weight loss, GLP-1s looked like a silver bullet for obesity. Today, they're a fully loaded magazine of silver bullets aimed at obesity, addiction, cancer, sleep apnea, and a growing list of other diseases and chronic conditions. The velocity of innovation is remarkable.
Usually when a new medicine happens, we have time to learn how to use it, Dr. Melanie Jay, director of the NYU Langone Comprehensive Program on Obesity, told the New York Times. But with GLP-1s, everyone is kind of iterating in real time. Some recent iterations. Last month, Eli Lilly announced that its phase 3 trial for retitrutide, a triple agonist dubbed Godzilla that activates GLP-1, GIP, and glucagon receptors, appears to exceed the performance of other weight loss medications. On average, patients on ZepBound or Wegovi lose between 14% and 20% of their initial body weight over 72 weeks.
Patients in the retitrutide trial taking 4mg, 9mg, and 12mg doses lost an average of 19%, 26%, and 29% of their starting weight, respectively. But the most promising drug is Foundeo, a daily pill from Eli Lilly the FDA approved for weight loss in April. In clinical trials, it resulted in 12% weight loss over 72 weeks. Less effective than shots, but a good alternative for the 66 million Americans who are afraid of needles. The pills also show a promise as a maintenance tool. As Nicholas Florco wrote in The Atlantic, America has a new GLP-1 playbook, with a shot to lose weight and a pill to keep it off. In the U.S., one in eight adults currently take a GLP-1, with prescriptions for weight loss doubling from 2024 to 2025. It's working.
A year after the drugs were approved for weight loss, the U.S. obesity rate peaked at 40%, but it has since begun to decline. Sadly, GLP-1s haven't had the same impact on their initial target, diabetes. William Gibson famously said, The future is already here, it's just not evenly distributed. He could have been describing GLP-1s. A recent Cleveland Clinic study found that cost is by far the primary reason people quit, with 47% of those who discontinued the drugs citing insurance denial, expiration of a discount coupon, or unaffordable out-of-pocket expenses.
Side effects were the second most common reason, cited by 14% of respondents, while less than 2% quit due to unsatisfactory weight loss. In other words, GLP-1s can change society if we distribute them to everyone who needs them, regardless of their ability to pay. The good news? Beginning July 1, Medicare Part D will cover certain GLP-1 treatments with a $50 monthly copay for seniors. The bad news? Private insurance plans, which provide pharmaceutical benefits for two-thirds of Americans, are scaling back GLP-1 coverage if they even offered it to begin with.
According to the Wall Street Journal, 11% of employers have dropped or are planning to drop GLP-1 coverage for weight loss altogether, and more than a quarter of big companies are adding hurdles, such as requiring multiple weigh-ins a month, meal tracking on apps, or mandatory health coaching. The U.S. is simultaneously hitting the gas while pumping the brakes on the best tool we have for combating obesity. With a few exceptions, the 17 companies valued at $1 trillion or more are all technology companies heavily invested on AI. The only drugmaker on the list is Eli Lilly, whose shares have registered a 418% increase since GLP-1s were first approved for weight loss in 2021. Novo Nordisk, Eli Lilly's chief competitor and the maker of Ozempic and Wagovi, is up just 2% over the same period. The discrepancy points to something unusual about the dynamics of GLP-1 pricing.
Typically, drug prices are inelastic, i.e. consumers aren't very responsive to price changes unless a generic option is available. But as one industry analyst explained, the obesity market has turned traditional pharma economics upside down. Eli Lilly's products have a perceived efficacy edge, but the company also beat Novo Nordisk to the direct-to-consumer market. On my podcast, Eli Lilly chair and CEO David Ricks told me, in the GLP-1 category, we observe prices are elastic. The more we lower the price, the more users we get.
That's the path we're on. GLP-1s may be the rare pharmaceutical case where capitalism is on the consumer side. But Ricks also told me GLP-1s are unique insofar as nearly everyone who takes them loses weight. Unlike drugs for other chronic conditions, people like being on GLP-1s because they notice results in their appearance rather than intangible health benefits and side effects. The fine print? Many people may never stop taking GLP-1s, creating an enduring subscription business.
Think Netflix, but with monthly prices ranging from $149 to $499, and instead of market competition, a duopoly. GLP-1s may not be an off-ramp from the industrial food medical pharma complex, but the ultimate physiological lock-in. Victoria's Secret shares surged 47% last week after the company reported 15% year-over-year revenue growth and raised full-year sales guidance to $7.1 billion. Meanwhile, fast food chains are shrinking their footprint, with Jack in the Box, Pizza Hut, and Wendy's among the brands closing hundreds of stores nationwide. That's yet another bad sign for an industry that's registered more than 500 franchisee bankruptcies this year. U.S. alcohol sales are also down, with Diageo and Pernod Ricard reporting a 15% decline year over year, while Constellation brands saw a 10% drop.
CEOs have blamed tariffs, affordability, and in the case of alcohol, Gen Z. But GLP-1s are a more likely explanation for the shift in consumer behavior. More signals? The share of apparel exchanges where shoppers size down has risen for three consecutive years, hitting a 14% high among online retailers. Adults who use GLP-1s consume 21% fewer calories and spend nearly a third less on groceries on average. Meanwhile, 59% of Americans say they'd be more likely to visit restaurants that serve flexible, customizable, or innovative portion size options. And that goes up to 73% among GLP-1 users. The same report noted that 13% of restaurant operators have listed items that appeal to GLP-1 users, higher protein and or fiber, and 42% say they're considering such additions.
There will be downstream effects. A significant decline in fast food revenue will accelerate closures across the industry's 200,000 plus U.S. locations, destabilizing commercial real estate markets and threatening the livelihoods of the 4 million people who work in the sector. Apparel brands that built supply chains around stable sizes and predictable returns will have to adjust to hit a moving target. America's shrinking waistline.
The AI narrative has turned negative. Energy costs are up, jobs are supposedly going away, relationships are going virtual, and if the technology advances as promised, it presents a threat to humanity. The GLP-1 story offers something Silicon Valley used to produce in abundance, a hopeful vision of the future. Every American knows people who struggle with their weight. We all know someone who has a chance to live longer, do more, and feel better about themselves because of GLP-1s.
A nation's greatness isn't measured in GDP, but in the quality of life its citizens enjoy. For the first time in decades, American innovation is adding years to lives, not just zeros to valuations. The question isn't whether GLP-1s will change the US. They already have. The question is whether we'll be stupid enough to ration the change. Life is so rich.
Support for the show comes from USA Facts. Income inequality, entitlements, housing costs. Want to really see what the government is up to, what it costs, and who is benefiting? Check out a debate on the American dream between Scott Galloway and Ben Shapiro. It's not your typical soundbites from boring politicians reading talking points. The debate is framed by an informative set of government facts from USA Facts. And then Ben and Scott get into it. There are sharp differences, some common ground, and data and facts that leave you knowing more. Check out the full debate now on the USA Facts YouTube channel.
Support for the show comes from CoreWeave. Everywhere you look, AI is expanding what we thought was possible. And at the center of it all is CoreWeave. Medical research and diagnosis, education, complex visual effects for movies, science and technology breakthroughs. CoreWeave powers AI pioneers around the world with purpose-built tech, building what's never been built before. CoreWeave is the essential cloud for AI. Ready for anything, ready for AI. To learn more about how CoreWeave powers the world's best AI, go to coreweave.com slash ready for anything.
There are sales teams out there who never seem to stop moving. Always a step ahead, always working with a level of precision that doesn't seem normal. It's no secret they're on Atio, the agentic CRM. Atio runs the work behind every win. It's built for humans and agents with the guardrails of human software and the scale of agentic infrastructure. This is the frontier of go-to-market. Teams like Parallel, Turbo Puffer, and Wordsmith are already using Atio to set the pace. Now it's your turn. Try Atio for free by going to atio.com slash fox. That's A-T-T-I-O dot com slash fox.